Spots Global Cancer Trial Database for exemestane
Every month we try and update this database with for exemestane cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | NCT04300790 | Breast Cancer | Alpelisib Metformin Fulvestrant Letrozole Exemestane Vildagliptin Tamoxifen | 18 Years - | MedSIR | |
| Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | NCT01153672 | Male Breast Can... Recurrent Breas... Stage IV Breast... | vorinostat laboratory biom... biopsy F-18 16 alpha-f... positron emissi... anastrozole letrozole exemestane gene expression... | 18 Years - | University of Washington | |
| Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy | NCT00688194 | Breast Cancer | anastrozole exemestane fulvestrant lapatinib ditos... letrozole placebo | 18 Years - | National Cancer Institute (NCI) | |
| Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | NCT04852081 | Breast Cancer S... | Palbociclib Ribociclib Abemaciclib Letrozole Anastrozole Tamoxifen Fulvestrant Exemestane Alpelisib | 18 Years - | Blokhin's Russian Cancer Research Center | |
| A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer | NCT00417885 | Breast Neoplasm... | exemestane sunitinib malat... | 18 Years - | Pfizer | |
| Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors | NCT02028507 | Metastatic Brea... | Palbociclib Capecitabine Exemestane Fulvestrant | 18 Years - | Spanish Breast Cancer Research Group | |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | NCT03280563 | Breast Neoplasm... | Atezolizumab (M... Bevacizumab Entinostat Exemestane Fulvestrant Ipatasertib Tamoxifen Abemaciclib | 18 Years - | Hoffmann-La Roche | |
| Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer | NCT04272801 | Breast Cancer F... | tamoxifen, letr... Patient reporte... | 65 Years - | University of Virginia | |
| Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer | NCT00083174 | Breast Cancer | exemestane | 35 Years - | Canadian Cancer Trials Group | |
| Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer | NCT01385280 | Estrogen Recept... Progesterone Re... Recurrent Breas... Stage IIIC Brea... Stage IV Breast... | therapeutic est... exemestane laboratory biom... enzyme-linked i... | - | University of Arizona | |
| Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer | NCT00525096 | Metastatic Brea... | placebo Celecoxib Exemestane | 18 Years - | ARCAGY/ GINECO GROUP | |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT01626222 | Metastatic Brea... | Exemestane Everolimus (RAD... | 18 Years - | Novartis | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | NCT02947685 | HER-2 Positive ... Estrogen Recept... | palbociclib trastuzumab pertuzumab letrozole Anastrozole Exemestane Fulvestrant | 18 Years - | Alliance Foundation Trials, LLC. | |
| Exemestane and Cyclophosphamide for Metastatic Breast Cancer | NCT01963481 | Metastatic Beas... | Exemestane Cyclophosphamid... | 18 Years - | NYU Langone Health | |
| To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy | NCT02549430 | Breast Cancer | Palbociclib Anastrozole Letrozole Exemestane Fulvestrant | 18 Years - | Fondazione Sandro Pitigliani | |
| The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer | NCT00065325 | Locally Advance... Metastatic Brea... | Fulvestrant Exemestane | 32 Years - 91 Years | AstraZeneca | |
| Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer | NCT04869943 | Metastatic Brea... | Enobosarm Exemestane | 18 Years - 100 Years | Veru Inc. | |
| Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer | NCT02910050 | Breast Cancer | Bicalutamide Aromatase Inhib... | 18 Years - 80 Years | Sun Yat-sen University | |
| Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer | NCT01698918 | Hormone Recepto... | Everolimus Letrozole Exemestane Alcohol-free de... Standard of car... | 18 Years - | Novartis | |
| Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer | NCT02069093 | Advanced Breast... | Dexamethasone b... Everolimus Exemestane | 18 Years - | Novartis | |
| BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors | NCT01938846 | Neoplasms | BI 860585 exemestane BI 860585 BI 860585 paclitaxel | 18 Years - 99 Years | Boehringer Ingelheim | |
| Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer | NCT04460807 | Ovarian Cancer | Exemestane Placebo oral ta... | 18 Years - | Ente Ospedaliero Ospedali Galliera | |
| Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer | NCT00931450 | Breast Cancer | exemestane sunitinib malat... placebo | - | National Cancer Institute (NCI) | |
| Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer | NCT02049957 | Breast Cancer | Sapanisertib Fulvestrant Exemestane | 18 Years - | Calithera Biosciences, Inc | |
| Aromatase Inhibitor Clinical Trial | NCT00228956 | Breast Cancer | pharmacodynamic... | 40 Years - 70 Years | National Institute of General Medical Sciences (NIGMS) | |
| Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy | NCT03220178 | Breast Neoplasm | Palbociclib Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Palleos Healthcare GmbH | |
| A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) | NCT01234857 | Breast Cancer | ridaforolimus +... exemestane ridaforolimus dalotuzumab | 18 Years - | Merck Sharp & Dohme LLC | |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | NCT06016738 | Breast Cancer Advanced Breast... Metastatic Brea... ER Positive Bre... HER2 Negative B... | Palazestrant Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Olema Pharmaceuticals, Inc. | |
| Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers | NCT00941330 | Breast Cancer | Exemestane Docetaxel Cytoxan | 18 Years - | Emory University | |
| Exemestane-RAD001-Metformin | NCT01627067 | Breast Cancer | Everolimus Exemestane Metformin | 18 Years - | M.D. Anderson Cancer Center | |
| Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer | NCT06361940 | Breast Cancer | Aromatase inhib... | 18 Years - | Medical College of Wisconsin | |
| Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant | NCT00919399 | Breast Neoplasm... | Exemestane tamoxifen | 60 Years - | Institut Claudius Regaud | |
| A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC | NCT02592746 | Metastatic Brea... | Palbociclib Exemestane Leuprolide Acet... Capecitabine | 19 Years - | Samsung Medical Center | |
| Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer | NCT00010010 | Breast Cancer | exemestane goserelin aceta... | 18 Years - 120 Years | NYU Langone Health | |
| Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not | NCT01553903 | Breast Cancer | Tamoxifen, Exemestane Anastrozole Letrozole | 18 Years - | Institut Claudius Regaud | |
| Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer | NCT00038467 | Breast Neoplasm... | Tamoxifen Exemestane | 30 Years - | Pfizer | |
| Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | NCT05467891 | Locoregional Re... Hormone Recepto... HER2-negative B... | Ribociclib Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Hoosier Cancer Research Network | |
| A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | NCT01783444 | Breast Cancer | Capecitabine Exemestane Everolimus | 18 Years - | Novartis | |
| Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer | NCT06361940 | Breast Cancer | Aromatase inhib... | 18 Years - | Medical College of Wisconsin | |
| A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) | NCT01605396 | Breast Neoplasm... | Ridaforolimus Dalotuzumab Exemestane | 18 Years - | Merck Sharp & Dohme LLC | |
| Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer | NCT00687648 | Breast Cancer | anastrozole cyclophosphamid... exemestane letrozole methotrexate prednisolone | 18 Years - | National Cancer Institute (NCI) | |
| S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | NCT01674140 | Breast Cancer | anastrozole everolimus exemestane goserelin aceta... letrozole leuprolide acet... tamoxifen citra... placebo | 18 Years - | SWOG Cancer Research Network | |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | NCT01626222 | Metastatic Brea... | Exemestane Everolimus (RAD... | 18 Years - | Novartis | |
| Exemestane and Cyclophosphamide for Metastatic Breast Cancer | NCT01963481 | Metastatic Beas... | Exemestane Cyclophosphamid... | 18 Years - | NYU Langone Health | |
| Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer | NCT00031889 | Prostate Cancer | Exemestane Exemestane+bica... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer | NCT00010010 | Breast Cancer | exemestane goserelin aceta... | 18 Years - 120 Years | NYU Langone Health | |
| Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | NCT00253422 | Breast Cancer | anastrozole exemestane fulvestrant | - | National Cancer Institute (NCI) | |
| Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer | NCT00038467 | Breast Neoplasm... | Tamoxifen Exemestane | 30 Years - | Pfizer | |
| Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer | NCT00057993 | Breast Cancer | trastuzumab exemestane | 18 Years - | Northwestern University | |
| Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients | NCT00128843 | Breast Cancer | Exemestane Anastrozole | 18 Years - 90 Years | Spanish Breast Cancer Research Group | |
| A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) | NCT01234857 | Breast Cancer | ridaforolimus +... exemestane ridaforolimus dalotuzumab | 18 Years - | Merck Sharp & Dohme LLC | |
| GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | NCT02983604 | Advanced Estrog... | GS-5829 Exemestane Fulvestrant | 18 Years - | Gilead Sciences | |
| Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD | NCT01655004 | Breast Carcinom... | Exemestane | 21 Years - 99 Years | National University Hospital, Singapore | |
| Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers | NCT00941330 | Breast Cancer | Exemestane Docetaxel Cytoxan | 18 Years - | Emory University | |
| Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer | NCT04465097 | Breast Cancer | Tucidinostat Exemestane Ovarian functio... | 18 Years - | First Affiliated Hospital, Sun Yat-Sen University | |
| Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles | NCT01626144 | Breast Cancer | 18 Years - | Milton S. Hershey Medical Center | ||
| Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD | NCT01655004 | Breast Carcinom... | Exemestane | 21 Years - 99 Years | National University Hospital, Singapore | |
| Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer | NCT00080613 | Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | exemestane adjuvant therap... aromatase inhib... conventional su... endocrine thera... hormone therapy neoadjuvant the... surgery | - | National Cancer Institute (NCI) | |
| 500mg Fulvestrant Versus Exemestane in MBC | NCT03575260 | Breast Cancer | 18 Years - | Fudan University | ||
| A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | NCT02057133 | Breast Neoplasm... | LY2835219 Letrozole Anastrozole Tamoxifen Exemestane Everolimus Trastuzumab LY3023414 Fulvestrant Pertuzumab Loperamide Endocrine thera... | 18 Years - | Eli Lilly and Company | |
| The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread | NCT03659136 | Breast Neoplasm... | Xentuzumab Placebo Everolimus Exemestane | 18 Years - | Boehringer Ingelheim | |
| Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer | NCT00265759 | Breast Cancer | anastrozole exemestane letrozole Therapeutic Con... | - | Alliance for Clinical Trials in Oncology | |
| Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | NCT00253422 | Breast Cancer | anastrozole exemestane fulvestrant | - | National Cancer Institute (NCI) | |
| S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | NCT01674140 | Breast Cancer | anastrozole everolimus exemestane goserelin aceta... letrozole leuprolide acet... tamoxifen citra... placebo | 18 Years - | SWOG Cancer Research Network | |
| Exemestane in Post-Menopausal Women With NSCLC | NCT02666105 | Non-Small Cell ... | Exemestane | - | Masonic Cancer Center, University of Minnesota | |
| Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer | NCT00687648 | Breast Cancer | anastrozole cyclophosphamid... exemestane letrozole methotrexate prednisolone | 18 Years - | National Cancer Institute (NCI) | |
| Adjuvant Post-Tamoxifen Exemestane Trial | NCT00810706 | Breast Cancer | exemestane | 18 Years - 80 Years | Hellenic Breast Surgeons Society | |
| Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | NCT06179303 | Anatomic Stage ... Anatomic Stage ... Locally Advance... Locally Advance... Metastatic HER2... Metastatic Horm... | Abemaciclib Anastrozole Biospecimen Col... Computed Tomogr... Diagnostic Imag... Exemestane Fludeoxyglucose... Fluorine F 18 F... Fulvestrant Gonadotropin-re... Letrozole Positron Emissi... Tamoxifen Therapeutic Est... | 18 Years - | University of Washington | |
| Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions | NCT01331421 | Breast Cancer | exemestane | 18 Years - 55 Years | West-Ward Pharmaceutical | |
| Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer | NCT00810797 | Breast Cancer | exemestane laboratory biom... quality-of-life... immunohistochem... | 18 Years - | City of Hope Medical Center | |
| A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | NCT01783444 | Breast Cancer | Capecitabine Exemestane Everolimus | 18 Years - | Novartis | |
| Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer | NCT02598557 | Stage 0 Breast ... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... | Exemestane Laboratory Biom... Pharmacological... Placebo Adminis... Quality-of-Life... Questionnaire A... Therapeutic Con... | - 75 Years | National Cancer Institute (NCI) | |
| ER Reactivation Therapy for Breast Cancer | NCT02188745 | Metastatic Brea... | 17B-estradiol Letrozole Anastrozole Exemestane | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| The Impact of Obesity and Obesity Treatments on Breast Cancer | NCT00933309 | Breast Cancer | Exemestane Avandamet | 18 Years - | M.D. Anderson Cancer Center | |
| Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD | NCT01655004 | Breast Carcinom... | Exemestane | 21 Years - 99 Years | National University Hospital, Singapore | |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer | NCT02392611 | Solid Tumors an... | Alobresib Exemestane Fulvestrant | 18 Years - | Gilead Sciences | |
| Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer | NCT00066703 | Breast Cancer | exemestane tamoxifen triptorelin | 18 Years - 65 Years | ETOP IBCSG Partners Foundation | |
| Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant | NCT02894398 | Breast Cancer Hormone Recepto... Human Epidermal... | Palbociclib Letrozole Anastrozole Exemestane Fulvestrant | 18 Years - | iOMEDICO AG | |
| Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | NCT01153672 | Male Breast Can... Recurrent Breas... Stage IV Breast... | vorinostat laboratory biom... biopsy F-18 16 alpha-f... positron emissi... anastrozole letrozole exemestane gene expression... | 18 Years - | University of Washington | |
| Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer | NCT00279448 | Breast Neoplasm... | exemestane tamoxifen | 50 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
